Advanced search
Publication Cover
Future Lipidology Volume 1, 2006 - Issue 6
Journal homepage
1,427
Views
3
CrossRef citations to date
0
Altmetric
Editorial

Fusogenic liposomes and their suitability for gene delivery

Tomoaki YoshikawaUniversity of Aarhus, Department of Medical Biochemistry, Jaharis 261,150 Harrison Avenue, DK, 8000, Aarhus C, Denmark, Tel.: +45 8942 2882; Fax.: +45 8613 1160, E-mail: [email protected]Correspondence[email protected]
,
Naoki OkadaUniversity of Copenhagen, Department of Clinical Biochemistry, Rigshospitalet, DK-2100, Copenhagen, Denmark, Tel.: +45 3545 2304; Fax.: +45 3545 2524, E-mail: [email protected]
&
Shinsaku NakagawaUniversity of Aarhus, Department of Medical Biochemistry, Jaharis 261,150 Harrison Avenue, DK, 8000, Aarhus C, Denmark, Tel.: +45 8942 2882; Fax.: +45 8613 1160, E-mail: [email protected]
Pages 735-742 | Published online: 18 Jan 2017

  • Lu PY, Xie F, Woodle MC: In vivo application of RNA interference: from functional genomics to therapeutics. Adv. Genet. 54, 117–142 (2005).
  • Zhang YC, Taylor MM, Samson WK, Phillips MI: Antisense inhibition: oligonucleotides, ribozymes, and siRNAs. Methods Mol. Med. 106, 11–34 (2005).
  • Lu PY, Xie FY, Woodle MC: siRNAmediated antitumorigenesis for drug target validation and therapeutics. Curr. Opin. Mol. Ther. 5(3), 225–234 (2003).
  • Luo D, Saltzman WM: Synthetic DNA delivery systems. Nat. Biotechnol. 18(1), 33–37 (2000).
  • Wiethoff CM, Middaugh CR: Barriers to nonviral gene delivery. J. Pharm. Sci. 92(2), 203–217 (2003).
  • Nishikawa M, Huang L: Nonviral vectors in the new millennium: delivery barriers in gene transfer. Hum. Gene Ther. 12(8), 861–870 (2001).
  • Mizuguchi H, Nakanishi M, Nakanishi T, Nakagawa T, Nakagawa S, Mayumi T: Application of fusogenic liposomes containing fragment A of diphtheria toxin to cancer therapy. Br. J. Cancer 73(4), 472–476 (1996).
  • Nakanishi M, Mizuguchi H, Ashihara K et al.: Gene delivery systems using the Sendai virus. Mol. Membr. Biol. 16(1), 123–127 (1999).
  • Nakanishi M, Mizuguchia H, Ashihara K et al.: Gene transfer vectors based on Sendai virus. J. Control Release 54(1), 61–68 (1998).
  • Yoshikawa T, Imazu S, Gao JQ et al.: Augmentation of antigen-specific immune responses using DNA-fusogenic liposome vaccine. Biochem. Biophys. Res. Commun. 325(2), 500–505 (2004).
  • Yoshikawa T, Tsutsumi Y, Nakagawa S: Development of nanomedicine using intracellular DDS. Nippon Rinsho 64(2), 247–252 (2006).
  • Yoshikawa T, Imazu S, Gao JQ et al.: Non-methylated CpG motif packaged into fusogenic liposomes enhance antigenspecific immunity in mice. Biol. Pharm. Bull. 29(1), 105–109 (2006).
  • Yoshikawa T, Okada N, Tsujino M et al.: Vaccine efficacy of fusogenic liposomes containing tumor cell-lysate against murine B16BL6 melanoma. Biol. Pharm. Bull. 29(1), 100–104 (2006).
  • Kunisawa J, Masuda T, Katayama K et al.: Fusogenic liposome delivers encapsulated nanoparticles for cytosolic controlled gene release. J. Control Release 105(3), 344–353 (2005).
  • Sugita T, Yoshikawa T, Gao JQ et al.: Fusogenic liposome can be used as an effective vaccine carrier for peptide vaccination to induce cytotoxic T lymphocyte (CTL) response. Biol. Pharm. Bull. 28(1), 192–193 (2005).
  • Nakanishi T, Hayashi A, Kunisawa J et al.: Fusogenic liposomes efficiently deliver exogenous antigen through the cytoplasm into the MHC class I processing pathway. Eur. J. Immunol. 30(6), 1740–1747 (2000).
  • Markwell MA, Paulson JC: Sendai virus utilizes specific sialyloligosaccharides as host cell receptor determinants. Proc. Natl Acad. Sci. USA 77(10), 5693–5697 (1980).
  • Hosaka Y: Sendai virion structure and its interaction with cellular membranes. Electron Microsc. Rev. 1(1), 17–38 (1988).
  • Ishida N, Homma M: Sendai virus. Adv. Virus Res. 23, 349–383 (1978).
  • Uchida T, Kim J, Yamaizumi M, Miyake Y, Okada Y: Reconstitution of lipid vesicles associated with HVJ (Sendai virus) sikes. Purification and some properties of vesicles containing nontoxic fragment A of diphtheria toxin. J. Cell Biol. 80(1), 10–20 (1979).
  • Nakanishi M, Uchida T, Sugawa H, Ishiura M, Okada Y: Efficient introduction of contents of liposomes into cells using HVJ (Sendai virus). Exp. Cell Res. 159(2), 399–409 (1985).
  • Mizuguchi H, Nakanishi T, Kondoh M et al.: Fusion of Sendai virus with liposome depends on only F protein, but not HN protein. Virus Res. 59(2), 191–201 (1999).
  • Kunisawa J, Nakagawa S, Mayumi T: Pharmacotherapy by intracellular delivery of drugs using fusogenic liposomes: application to vaccine development. Adv. Drug Deliv. Rev. 52(3), 177–186 (2001).
  • Mizuguchi H, Nakagawa T, Nakanishi M, Imazu S, Nakagawa S, Mayumi T: Efficient gene transfer into mammalian cells using fusogenic liposome. Biochem. Biophys. Res. Commun. 218(1), 402–407 (1996).
  • Mizuguchi H, Nakagawa T, Toyosawa S et al.: Tumor necrosis factor -mediated tumor regression by the in vivo transfer of genes into the artery that leads to tumors. Cancer Res. 58(24), 5725–5730 (1998).
  • Shiver JW, Davies ME, Perry HC, Freed DC, Liu MA: Humoral and cellular immunities elicited by HIV-1 vaccination. J. Pharm. Sci. 85(12), 1317–1324 (1996).
  • Webster RG, Fynan EF, Santoro JC, Robinson H: Protection of ferrets against influenza challenge with a DNA vaccine to the haemagglutinin. Vaccine 12(16), 1495–1498 (1994).
  • Donnelly JJ, Friedman A, Martinez D et al.: Preclinical efficacy of a prototype DNA vaccine: enhanced protection against antigenic drift in influenza virus. Nat. Med. 1(6), 583–587 (1995).
  • Fynan EF, Webster RG, Fuller DH, Haynes JR, Santoro JC, Robinson HL: DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc. Natl Acad. Sci. USA 90(24), 11478–11482 (1993).
  • Wang R, Doolan DL, Le TP et al.: Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 282(5388), 476–480 (1998).
  • Zhang L, Widera G, Bleecher S, Zaharoff DA, Mossop B, Rabussay D: Accelerated immune response to DNA vaccines. DNA Cell Biol. 22(12), 815–822 (2003).
  • Cohen AD, Boyer JD, Weiner DB: Modulating the immune response to genetic immunization. Faseb J. 12(15), 1611–1626 (1998).
  • Scheerlinck JY: Genetic adjuvants for DNA vaccines. Vaccine 19(17–19), 2647–2656 (2001).
  • Kawabata K, Takakura Y, Hashida M: The fate of plasmid DNA after intravenous injection in mice: involvement of scavenger receptors in its hepatic uptake. Pharm. Res. 12(6), 825–830 (1995).
  • Parker SE, Vahlsing HL, Serfilippi LM et al.: Cancer gene therapy using plasmid DNA: safety evaluation in rodents and non-human primates. Hum. Gene Ther. 6(5), 575–590 (1995).
  • Lew D, Parker SE, Latimer T et al.: Cancer gene therapy using plasmid DNA: pharmacokinetic study of DNA following injection in mice. Hum. Gene Ther. 6(5), 553–564 (1995).
  • Cui Z, Mumper RJ: The effect of co-administration of adjuvants with a nanoparticle-based genetic vaccine delivery system on the resulting immune responses. Eur. J. Pharm. Biopharm. 55(1), 11–18 (2003).
  • Gregoriadis G, Saffie R, de Souza JB: Liposome-mediated DNA vaccination. FEBS Lett. 402(2–3), 107–110 (1997).
  • Locher CP, Putnam D, Langer R, Witt SA, Ashlock BM, Levy JA: Enhancement of a human immunodeficiency virus env DNA vaccine using a novel polycationic nanoparticle formulation. Immunol. Lett. 90(2–3), 67–70 (2003).
  • Mumper RJ, Cui Z: Genetic immunization by jet injection of targeted pDNA-coated nanoparticles. Methods 31(3), 255–262 (2003).
  • Cui Z, Hsu CH, Mumper RJ: Physical characterization and macrophage cell uptake of mannan-coated nanoparticles. Drug Dev. Ind. Pharm. 29(6), 689–700 (2003).
  • Cui Z, Baizer L, Mumper RJ: Intradermal immunization with novel plasmid DNA coated nanoparticles via a needle-free injection device. J. Biotechnol. 102(2), 105–115 (2003).
  • Cui Z, Mumper RJ: Intranasal administration of plasmid DNA-coated nanoparticles results in enhanced immune responses. J. Pharm. Pharmacol. 54(9), 1195–1203 (2002).
  • Opalinska JB, Gewirtz AM: Nucleic-acid therapeutics: basic principles and recent applications. Nat. Rev. Drug Discov. 1(7), 503–514 (2002).
  • Suwanmanee T, Sierakowska H, Fucharoen S, Kole R: Repair of a splicing defect in erythroid cells from patients with -thalassemia/HbE disorder. Mol. Ther. 6(6), 718–726 (2002).
  • Song E, Lee SK, Wang J et al.: RNA interference targeting Fas protects mice from fulminant hepatitis. Nat. Med. 9(3), 347–351 (2003).
  • Moghimi SM, Hunter AC, Murray JC: Nanomedicine: current status and future prospects. Faseb J. 19(3), 311–330 (2005).
  • LaVan DA, McGuire T, Langer R: Smallscale systems for in vivo drug delivery. Nat. Biotechnol. 21(10), 1184–1191 (2003).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.